Canal Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Canal Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.49M	Buy	+9,045	New	+$4.01M	0.55%	53
2021 Q3	–	Sell	-2,018	Closed	-$407K	–	139
2021 Q2	$407K	Sell	2,018 -5,320	-72%	-$1.11M	0.12%	102
2021 Q1	$1.58M	Buy	7,338 +374	+5%	+$82.1K	0.54%	59
2020 Q4	$1.65M	Buy	6,964 +1,430	+26%	+$328K	0.62%	55
2020 Q3	$1.51M	Buy	+5,534	New	+$1.53M	0.66%	52

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Canal Capital Management's VRTX Position: Q2 2026 in Review

Canal Capital Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 9,045 shares worth $4.49M. The stake represents 0.55% of the portfolio and ranks #53 among its holdings. This is a return to the name: Canal Capital Management previously reported a position in VRTX as recently as Q2 2021.

Canal Capital Management first reported a position in VRTX in Q3 2020 and has held it in 5 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Canal Capital Management held 9,045 shares of Vertex Pharmaceuticals worth $4.49M as of Q2 2026.
Vertex Pharmaceuticals was a new Canal Capital Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.55% of Canal Capital Management's portfolio in Q2 2026, its #53 holding.
Canal Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 5 quarters since.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Canal Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.